Yongli Guo, Andrey V Dolinko, Fadzai Chinyengetere, Bruce Stanton, Jennifer M Bomberger, Eugene Demidenko, Da-Cheng Zhou, Robert Gallagher, Tian Ma, Fabrizio Galimberti, Xi Liu, David Sekula, Sarah Freemantle, Ethan Dmitrovsky
More effective treatments for acute promyelocytic leukemia (APL) are needed. APL cell treatment with all-trans-retinoic acid (RA) degrades the chimeric, dominant-negative-acting transcription factor promyelocytic leukemia gene (PML)/RARα, which is generated in APL by chromosomal translocation. The E1-like ubiquitin-activating enzyme (UBE1L) associates with interferon-stimulated gene ISG15 that binds and represses PML/RARα protein. Ubiquitin protease UBP43/USP18 removes ISG15 from conjugated proteins. In this study, we explored how RA regulates UBP43 expression and the effects of UBP43 on PML/RARα stability and APL growth, apoptosis, or differentiation...
December 1, 2010: Cancer Research